Names Dr. Andrew Lewis as Chief Scientific Officer, Kieron Hall as Chief Marketing Officer, and Eric Bironneau as Chief Business Officer.
Achieves 47% sales growth in the region.
Aims to provide customers greater flexibility with a streamlined, efficient, and comprehensive solution for their manufacturing needs.
Expands its specialized analytical services.
Will offer clients a complete solution from bulk drug substance production through to finished drug product.
New facility includes 20KL of single use drug substance capacity coupled with drug product filling capacity of up to one million vials per day.
Provides Scorpius opportunities to support biomanufacturing programs focused on the nation’s medical countermeasure programs & more.
Expands manufacturing capacity and capabilities in New York to meet increasing prescription and consumer healthcare customer demand.
Aims to addresses critical supply chain challenges, offering comprehensive API and drug product solutions in North America.
Hart has led a successful career in the packaging industry since 2002.
Adds lab-to-market development, analytical services, device manufacture, fill/finish, final assembly, and secondary packaging.
Olon provides additional capacity to support Antheia’s continued scale up and commercialization of early products, including thebaine.
Accreditation covers a range of chemical testing and in vitro cytotoxicity testing for finished medical devices, medical device components, drugs and packaging.
Gains access to DragonFly’s micellar technology for chemistry-in-water processes.
Both facilities will be operational in Q3 2024.
For the four newly approved products, Rentschler provided consulting, regulatory services, process development, technology transfer and manufacturing.
GMP manufacturing area is designed to produce peptide APIs from gram to kilogram range for clinical phase 1 and 2 requirements.
Utilizes Planar Motor technology, a magnetically levitated transport system, and robotics for loading and unloading.
Incorporates flexibility and innovation in a higher-speed, single-sided platform.
Will highlight its biologics portfolio of solutions across upstream, downstream processing and final fill operations.